Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study

Hyogo, Hideyuki; Ikegami, Tadashi; Tokushige, Katsutoshi; Hashimoto, Etsuko; Inui, Kentaro; Matsuzaki, Yasushi; Tokumo, Hironori; Hino, Fumiaki; Tazuma, Susumu

doi:10.1111/j.1872-034x.2011.00849.x

Cited by 76 publications

(43 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 12 months, follow-up biopsies available for 13 NASH patients showed a slight, non-significant reduction of NASH activity score (NAS), while fibrosis stage did not change significantly [56]. In one more open-label study by the same Authors in patients with NASH and hyperlipidaemia [57], follow up biopsies were performed after 24 months of treatment with atorvastatin 10 mg. After treatment, liver macrovescicular steatosis and NAS score were significantly improved in both studies, whereas some patients had increased fibrosis stage.…”

Section: Statins For the Treatment Of Non-alcoholic Fatty Liver Diseamentioning

confidence: 99%

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Pastori¹,

Polimeni²,

Baratta³

et al. 2015

Digestive and Liver Disease

143

105

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease is an emerging liver disease in Western countries and the most frequent cause of incidental elevation of serum liver enzymes. Dyslipidaemia is frequently observed in patients with non-alcoholic fatty liver disease, and treatment of dyslipidaemia plays a critical role in the overall management of these patients. Moreover, coronary artery disease remains the most common cause of death. Statins are effective lipid-lowering agents, associated with a lowering the risk of cardiovascular events in several interventional randomized clinical trials. However, statins are often underused in patients with non-alcoholic fatty liver disease and many physicians are concerned about the prescription of statins to patients with unexplained persistent elevation of liver enzymes or active liver disease. Based on currently available data, statin therapy, at low-to-moderate doses, seems to be safe and has low liver toxicity. Treatment of dyslipidaemia in patients with non-alcoholic fatty liver disease is recommended and may also improve liver function tests. In these patients, the risks of not taking statins could outweigh the risks of taking the drug. Conversely, the usefulness of statins for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis is still a matter of debate and randomized clinical trials of adequate size and duration are required.

show abstract

Section: Statins For the Treatment Of Non-alcoholic Fatty Liver Diseamentioning

confidence: 99%

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Pastori¹,

Polimeni²,

Baratta³

et al. 2015

Digestive and Liver Disease

143

105

View full text Add to dashboard Cite

show abstract

“…Most showed that treatment with statins reduces hepatic steatosis [41,45,47,49] but in some there was no change [48,76]. In some studies, an improvement in inflammation was also observed [41,47,49] but not in others [45,48,76].…”

Section: Accepted Manuscriptmentioning

confidence: 94%

“…In some studies, an improvement in inflammation was also observed [41,47,49] but not in others [45,48,76]. However, fibrosis was not reduced in any study [41,45,47,48,76] except in a small preliminary report in 6 patients treated with rosuvastatin for 6 months [49]. In contrast, in the only placebocontrolled study with repeat biopsy in patients with NAFLD (n = 16), treatment with simvastatin 40 mg/day for 12 months had no effect on liver histology [53].…”

Section: Accepted Manuscriptmentioning

confidence: 96%

Nonalcoholic fatty liver disease and statins

et al. 2015

View full text Add to dashboard Cite

“…Pitavastatin Hyogo et al [34] did an open-label pilot study on the efficacy of 2 mg/day pitavastatin for 12 months in 20 patients with biopsy-proven NASH. They reported that pitavastatin improved the NASH-related metabolic parameters and the severity of hepatic steatosis according to the results of liver biopsy done at the end of the study.…”

Section: Statinsmentioning

confidence: 99%

Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies

2012

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is currently the most common cause of incidental abnormal liver tests and elevated serum liver enzyme activities in the developed world. Obesity, diabetes, and other components of the metabolic syndrome are frequently associated with the NAFLD. The treatment of NAFLD focuses on life-style modifications. Statins, fibrates, and other lipid-lowering agents have been proposed as effective lipid-lowering treatments in patients with NAFLD/NASH. However, clinicians are concerned that hyperlipidemic patients with NAFLD/NASH who are treated with statins could develop transaminitis. We assessed the efficacy and safety of lipid-lowering agents for NAFLD/NASH by reviewing reports of human studies including pilot, prospective, preliminary, and post hoc analysis studies on online databases during the period of 1980 to December 2012. The results of studies provide compelling evidence that lipid-lowering agents are safe and efficacious in patients with NAFLD/NASH and that some of these agents can induce a reduction in the extent of the hepatic steatosis. Well-designed randomized controlled studies of adequate size and duration with histological endpoints are needed in order to establish a suitable lipid-lowering treatment for hyperlipidemic patients with NAFLD/NASH, and for nonhyperlipidemic patients with NAFLD/NASH with a high risk for cardiovascular disease.

show abstract

Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study

Cited by 76 publications

References 57 publications

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Nonalcoholic fatty liver disease and statins

Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies

Contact Info

Product

Resources

About